Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tectonic Therapeutic (TECX)
NASDAQ:TECX
RESEARCH TOOLSreports
Holding TECX?
Track your performance easily
TECX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.12 - $48.63
Previous Close$38.88
Volume91.36K
Average Volume (3M)116.27K
Market Cap
$596.75M
Enterprise Value$440.64M
Total Cash (Recent Filing)$159.09M
Total Debt (Recent Filing)$2.98M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Nov 07, 2024EPS Estimate
-$0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.73
Shares Outstanding14,752,689
10 Day Avg. Volume156,316
30 Day Avg. Volume116,273
Standard Deviation0.23
R-Squared0.07
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)3.82
Price to Sales (P/S)11050.86
Price to Cash Flow (P/CF)-7.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.16K
Enterprise Value/Gross Profit-215.89
Enterprise Value/Ebitda-9.65
Forecast
1Y Price Target
$74.67Price Target Upside82.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Tectonic Therapeutic News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentTX45 demonstrated a half-life of 14-20 days in healthy volunteers, which is longer than LLY volenrelaxin’s 8-10 days and AZN AZD 3427’s 7-9 days.
Market PositionCross-trial comparisons indicate that TECX’s TX45 may offer a superior profile for potential monthly dosing.
Safety ProfileTX45 was well tolerated in healthy volunteers, with no dose-dependent safety events.
Bears Say
Clinical DevelopmentFailures in clinical development of all drugs studied in Group 2 PH.
Financial PerformanceHigher than estimated R&D expenses due to increased external CRO costs related to TX45 trials.
Market CompetitionPotential competition from major pharmaceutical companies like AZN, MRK, and LLY.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TECX FAQ
What was Tectonic Therapeutic’s price range in the past 12 months?
Tectonic Therapeutic lowest stock price was $12.12 and its highest was $48.63 in the past 12 months.
What is Tectonic Therapeutic’s market cap?
Currently, no data Available
When is Tectonic Therapeutic’s upcoming earnings report date?
Tectonic Therapeutic’s upcoming earnings report date is Nov 07, 2024 which is 44 days ago.
How were Tectonic Therapeutic’s earnings last quarter?
Tectonic Therapeutic released its earnings results on Aug 14, 2024. The company reported -$4.34 earnings per share for the quarter, missing the consensus estimate of -$1.303 by -$3.037.
Is Tectonic Therapeutic overvalued?
According to Wall Street analysts Tectonic Therapeutic’s price is currently Undervalued.
Does Tectonic Therapeutic pay dividends?
Tectonic Therapeutic does not currently pay dividends.
What is Tectonic Therapeutic’s EPS estimate?
Tectonic Therapeutic’s EPS estimate is -$0.84.
How many shares outstanding does Tectonic Therapeutic have?
Tectonic Therapeutic has 14,752,689 shares outstanding.
What happened to Tectonic Therapeutic’s price movement after its last earnings report?
Tectonic Therapeutic reported an EPS of -$4.34 in its last earnings report, missing expectations of -$1.303. Following the earnings report the stock price went down -3.022%.
Which hedge fund is a major shareholder of Tectonic Therapeutic?
Among the largest hedge funds holding Tectonic Therapeutic’s share is Farallon Capital Management, L.L.C.. It holds Tectonic Therapeutic’s shares valued at 13M.
---
Tectonic Therapeutic Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.67 (82.75% Upside)
$74.67 (82.75% Upside)
Insider Transactions
Bought Shares
Worth $11.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 67.1%
Last 30 Days ▲ 67.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
151.16%
12-Months-Change
Fundamentals
Return on Equity
-36.32%
Trailing 12-Months
Asset Growth
52.65%
Trailing 12-Months
Company Description
Tectonic Therapeutic
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.
---
TECX Stock 12 Month Forecast
Average Price Target
$74.67
▲(82.75% Upside)
Technical Analysis
Best Analysts Covering TECX
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+131.32%
assigned a buy rating last month
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +131.32% per trade.
---